JP2025501458A5 - - Google Patents

Info

Publication number
JP2025501458A5
JP2025501458A5 JP2024533944A JP2024533944A JP2025501458A5 JP 2025501458 A5 JP2025501458 A5 JP 2025501458A5 JP 2024533944 A JP2024533944 A JP 2024533944A JP 2024533944 A JP2024533944 A JP 2024533944A JP 2025501458 A5 JP2025501458 A5 JP 2025501458A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
day
disease
subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501458A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2022/051314 external-priority patent/WO2023112025A1/en
Publication of JP2025501458A publication Critical patent/JP2025501458A/ja
Publication of JP2025501458A5 publication Critical patent/JP2025501458A5/ja
Pending legal-status Critical Current

Links

JP2024533944A 2021-12-14 2022-12-13 疾患の性特異的治療のためのnap Pending JP2025501458A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163289174P 2021-12-14 2021-12-14
US63/289,174 2021-12-14
US202263306146P 2022-02-03 2022-02-03
US63/306,146 2022-02-03
PCT/IL2022/051314 WO2023112025A1 (en) 2021-12-14 2022-12-13 Nap for sex-specific treatment of diseases

Publications (2)

Publication Number Publication Date
JP2025501458A JP2025501458A (ja) 2025-01-22
JP2025501458A5 true JP2025501458A5 (https=) 2025-12-18

Family

ID=86773996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533944A Pending JP2025501458A (ja) 2021-12-14 2022-12-13 疾患の性特異的治療のためのnap

Country Status (9)

Country Link
US (1) US20250312408A1 (https=)
EP (1) EP4447994A4 (https=)
JP (1) JP2025501458A (https=)
KR (1) KR20240135692A (https=)
AU (1) AU2022410066A1 (https=)
CA (1) CA3240138A1 (https=)
IL (1) IL313226A (https=)
MX (1) MX2024006777A (https=)
WO (1) WO2023112025A1 (https=)

Similar Documents

Publication Publication Date Title
JP6466540B2 (ja) 多発性硬化症を治療するためのPPARγアゴニスト
US11918577B2 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
JP2019513814A5 (https=)
CN105873942A (zh) 使用pten抑制剂治疗损伤的神经
RS67601B1 (sr) Terapijski agensi za upotrebu u lečenju sindroma nemirnih nogu
JP2025501458A5 (https=)
EP3448431A1 (en) Highly selective adenosine a3 receptor subtype agonsists for the prevention and treatment of neurodegenerative disorders
Xu et al. Naloxone inhibition of lipopolysaccharide-induced activation of retinal microglia is partly mediated via the p38 mitogen activated protein kinase signalling pathway
CN114259486B (zh) 木犀草素及其药物组合物的应用
RU2267319C2 (ru) Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
RU2391095C1 (ru) Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
AU642045B2 (en) Pharmaceutical compositions for use in treating parkinson's disease
US11826340B1 (en) Method for treateing or preventing ischemic optic neuropathy
JP2004531480A (ja) 神経変性疾患の処置のためのトリペプチド誘導体
US20030064082A1 (en) Antipsychotic agents stimulate neurogenesis in brain
CN118831167A (zh) 用于治疗脑血管疾病与免疫系统紊乱的药物及其制备方法与应用
US20160367503A1 (en) Combination Medication for Neuro-Degenerative Diseases
RU2345786C2 (ru) Способ лечения непрерывно-прогредиентных дегенеративных и демиелинизирующих заболеваний
RS63859B1 (sr) N,n-bis-2-merkaptoetil izoftalamid za lečenje neurodegenerativnih bolesti
CN117599051A (zh) 小分子化合物在制备用于预防和治疗阿尔茨海默病的药物中的应用
Parise Prolactin and Risperidone in the current clinical practice: Results
Sturfelt et al. Acute Effects of Barbiturates in Parkinson's Disease: A Preliminary Communication with Case Reports
Gogitidze et al. P-12-7 Opposite effects of two different neurotropic drugs on parameters of mnestic function
Sherstnev et al. P-12-5 The effects of the synthetic peptide fragments of the nerve growth factors on memory
Harder et al. P-12-6 The effect of two putative cognitive enhancers, ondansetron and tacrine, on a rat water maze acquisition deficit produced by combined pCPA and scopolamine treatment